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Ovarian, endometrial and breast cancers are associated with several risk factors, such as low parity,
infertility, early age at menarche, and late age at menopause. Frequently most of these risk factors coexist
in infertile patients and some studies suggested that the different infertility causes can be involved in
cancer risk development. In particular case–control and cohort studies investigated the possible role of
ovulatory disorders, endometriosis and unexplained infertility in increasing the risk of this disease. Most
studies have shown no overall increased risk in invasive ovarian cancer in subfertile patients, although
nulliparity has been consistently associated with increased rates of ovarian tumor, in particular with
borderline and endometrioid cancers in patients with a history of endometriosis. Different studies
reported that infertile women are not at risk for breast cancer. However, women affected by infertility
may be more at risk for endometrial cancer, particularly if affected by ovulatory disorders.
Moreover, infertility is now often treated with medical devices that could by themselves modify the
hormonal environment and be cofactors in the cellular changes towards cancer development. However,
although early studies suggested that infertility medications were associated to increased risk in ovarian
cancer, subsequent studies have been mainly reassuring, although suggesting that type and duration of
medical treatment can increase the malignancy risk.
An increased risk of endometrial cancer in patients undergoing infertility treatment has been reported,
as expected by the similar structure shared by clomiphene and tamoxiphene.
Since breast cancer is widely recognized as having a hormonal etiology, a possible role of fertility
medications to promote cancer has been hypothesized. However, many large studies were not able to
ﬁnd an associated risk of breast cancer.
In conclusion, nowadays, ﬁrm answers about the precise effects of infertility and its treatment on cancer
risk are not available but ﬁndings are generally reassuring. Further studies about fertility drug treatments
on larger populations may offer in the future longer follow-up and more precise data with better
adjustments for confounding factors.
 2008 Published by Elsevier Ltd.
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OInfertility is a condition deﬁned by the inability to conceive, or toget pregnant, within 1 year. Infertility has been recognized by theWHO as a problem affecting between 15% and 20% of couples in
developed countries. Causes affecting the female are involved in
35–40% of cases. However, infertility is not a disease in itself, rather,
it can be the result of many different disorders, from malformative,
to endocrine, autoimmune, infective as well as psychological. Since
these factors involve the female reproductive system, concerns
have developed about the future health of these women, speciﬁ-
cally whether infertility would represent a risk factor for future
cancer development. Moreover, infertility is now often treated with
medications and procedures that could by themselves modify the
hormonal environment and be cofactors in the cellular changes
towards cancer development.: þ39 02 50319805.
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106
107
108
109This review addresses the potential association between infer-
tility and cancer development in females evaluated by both cohort
and case–control studies. Moreover, it focuses on the inﬂuence of
infertility treatment such as ovulation induction.
1. Ovarian cancer and infertility
Nulliparity itself represents a risk factor for epithelial ovarian
cancer. If Qinfertility per se could be a condition associated with
increased risk of ovarian cancer has been investigated by a signiﬁ-
cant number of cohort and case–control studies that are summa-
rized in Tables 1 and 2.
Numerous cohort studies have compared ovarian cancer rates in
subfertile women with those of the general population, using the
standardized incidence ratio (SIR) [1–7]. The potential limitation of
most of these studies is the small number of ovarian cancers and
the potential confounding factor of nulliparity. A higher incidence
in infertile women could indeed be attributable to nulliparity itself,actor – A Review, Placenta (2008), doi:10.1016/j.placenta.2008.08.007
EO
O
F
Table 1
Q7 Selected cohort studies studying the association between infertility (part A), fertility drugs (part B) and ovarian cancer risk
Authors Population No. of ovarian cancer Standardized incidence ratios (95% CIs) vs general population
Infertility and ovarian cancer risk
Brinton et al. [1] 2335 11 Evaluated for infertility 1.28 (not given)
Modan et al. [4] 2496 12 Infertility patients treated 1.6 (0.8–2.9)
Venn et al. [2] 29,700 13 IVF patients evaluated 0.99 (0.57–1.70)
Potashnik et al. [3] 1197 2 Evaluated for infertility 0.91 (0.1–3.27)
Rossing et al. [6] 3837 11 Evaluated for infertility 2.5 (1.3–4.5)
Brinton et al. [45] 12,193 45 Evaluated for infertility 1.98 (1.4–2.6)
Fertility drugs and ovarian cancer risk
Rossing et al. [6] 3837 11 No drug 1.4 (0.2–5.0)
Clomiphene 3.1 (1.4–5.9)
hMG/FSH 5.6 (0.1–31.0)
Modan et al. [4] 2496 12 No drug 1.6 (0.6–3.5)
All treatments 1.7 (0.6–3.8)
Clomiphene 2.7 (0.9–5.8)
Doyle et al. [52] 5556 6 No treatment 1.7 (0.2–6.0)
Treatment 0.6 (0.2–2.2)
Brinton et al. [45] 12,193 45 No clomiphene 2.1 (1.4–3.0)
Clomiphene 1.8 (1.0–3.0)
Klip et al. [46] 23,592 15 No IVF 1.4 (0.4–3.2)
IVF 1.4 (0.7–2.6)
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rather than to the infertile condition. The incidence of ovarian
cancer has been reported to be similar to the age-adjusted general
population incidence in all except for three large studies [5–8].
Brinton et al. in a cohort of US women [5], Venn et al. in a cohort of
Australian women [2], Potashnik et al. [3] and Modan et al. [4] in
cohorts of Israeli Women found no increased risk of ovarian cancer
compared to the general populationwith an average of follow-up at
least of 10 years [1–4]. An increased risk of ovarian cancer was
instead reported by Brinton et al. (SIR 1.98, 95% CI 1.4–2.6) Rossing
et al. (SIR 2.5, 95% CI 1.3–4.5) and recently by Tworoger et al. (Rate
ratio¼ 1.36, 95% CI: 1.07–1.75) [5–8]. The inclusion of borderline
tumors, which are known to be less aggressive and to have a better
prognosis than other malignant tumors, as well as invasive tumors
may explain the different data reported in Rossing’s study. Other
studies have reported borderline tumors to be increased in infertile
women [7]. Their increased detection in infertile women seeking
for infertility investigations may reﬂect selection biases rather than
a true increased incidence. Parity status adjustment which is the
most relevant confounding factor has been recently reported by
Jensen et al. [9]. This recent and large cohort study, including
54,362 women with diagnosis of infertility who were referred to
Danish fertility clinics between 1963 and 1998, using parity speciﬁc
cancer incidence, revealed a signiﬁcantly increased SIR for ovarian
cancer (1.46, 95% CI: 1.24–1.71) [9].
Some cohort studies offer internal comparisons within the
cohort of infertile women, which do allow adjustment for impor-
tant ovarian cancer risk predictors and try to clarify the real effectsU
NTable 2
Case–control studies studying the association between infertility (part A), fertility drugs
Authors No. of cases No. of controls
Infertility and ovarian cancer risk
Whittemore et al. [10] 2197 8893
Ness et al. [11] 5207 7705
Fertility drugs and ovarian cancer risk
Shu et al. [47] 229 229
Whittemore et al. [10] 718 1236
Franceschi et al. [48] 195 1339
Ness et al. [11] 149 911
Parazzini et al. [49] 971 2758
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of different and independent causes of infertility. After correcting
for age at menarche, breastfeeding, use of ovulation therapy, tubal
ligation, hysterectomy, age at menopause, menopausal hormone
use, Brinton et al. report no increased ovarian cancer risk associated
with ovulatory causes of infertility, fallopian tube dysfunction, or
male factor/mechanical subfertility, while endometriosis associ-
ated to primary infertility showed an RR of 2.27 [5]. Ovarian tumors
were roughly twice as likely to develop in women with ovulatory
abnormalities than in the infertile women with other types of
abnormalities [6].
Case–control studies have generally reported subfertility to be
weakly, but not signiﬁcantly, associated with increased rates of
ovarian cancer in nulligravid or nulliparous women, but not in
women who have ever been pregnant [10–12]. The most recent
well-conducted case–control study by Rossing et al. reported a non-
signiﬁcantly increased risk of epithelial ovarian cancer in nullipa-
rous (OR 1.3, 95% CI 0.7–2.5, NS) but not in parous women with
a history of subfertility [12]. Whittemore et al. [10] and Ness et al.
[11] conducted the largest pooled analysis of several case–control
studies. Whittemore et al. considered in the analysis 12 US case–
control studies carried out between 1957 and 1985, totalizing 2197
cases of ovarian cancer and 4144 controls with a history of sub-
fertility [10]. The analysis revealed a higher but not signiﬁcantly
increased risk of ovarian cancer in nulligravid subfertile women
than in gravid subfertile women (OR 1.4, 95% CI 0.86–2.3, NS vs OR
0.87, 95% CI 0.67–1.1, NS). Ness et al. considered in the analysis eight
case–control studies, summing up to 5207 cases of ovarian cancer(part B) and ovarian cancer risk
Comparison OR (95% CI)
12 US case–control studies (1956–1986) Nulligravid: 1.4 (0.86–0.23)
Gravid: 0.87 (0.67–1.1)
Eight case–control studies (1989–1999) Nulligravid: 1.1 (0.91–1.55)
Gravid: 1.1 (1.02–1.31)
Drugs vs no drugs use 2.1 (0.2–22.7)
Fertility drugs use vs no infertility 2.8 (1.3–6.1)
Drugs vs no drugs use 0.7 (0.2–3.3)
Drugs vs no drugs use 0.93 (0.7–1.2)
Drugs vs no drugs use 1.1 (0.4–3.3)
6 cycles 1.0 (0.2–3.8)
actor – A Review, Placenta (2008), doi:10.1016/j.placenta.2008.08.007
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and 7705 controls [11]. Overall, women seeking medical attention
for infertility had no increased risk of ovarian cancer. The sub-
analysis about nulligravid and gravid women found a weak asso-
ciation between potentially subfertile women with epithelial
ovarian cancer in gravid (OR 1.16, 95% CI 1.02–1.31) but not in
nulligravid women (OR 1.19, 95% CI 0.91–1.55 NS). It is interesting to
note that both meta-analysis revealed an increased rate of ovarian
cancer in women with prolonged infertility: Whittemore et al.
reported that nulligravid and gravid womenwith a history of more
than 15 years of unprotected intercourse had increased risk of
developing ovarian cancer compared to thosewith less than 2 years
of unprotected intercourse. Similarly, Ness et al. found that nulli-
gravid women with more than 5 years of baby seeking presented
a threefold increased risk of ovarian cancer than women who had
attempted for less than 1 year (OR 2.67, 95% CI 1.91–3.74) [10,11].
Some studies have also evaluated the speciﬁc cause of infertility
and the correlated risk of ovarian cancer [10,11,13]. Ovulatory
disorders, endometriosis, and unexplained infertility are the most
common diagnoses associated to ovarian cancer. Schildkraut et al.
reported a 2.4-fold (95% CI 1.0–5.9) increased risk in women
affected by polycystic ovary syndrome (PCOS) [13], while Whitte-
more et al. and Ness et al. in the sub-analysis of risk inwomenwith
infertility linked to ovulatory disorders did not report an increased
risk of ovarian cancer [10,11]. Unexplained infertility was reported
to be an independent risk factor for ovarian cancer in different
reports [2,14] and in themeta-analysis by Ness et al. [11], but not by
Whittemore et al. [10].
Endometriosis is the subtype of infertility with more agree-
ment between cohort and case–control studies associated to
cancer risk. Since endometriosis is a condition associated to
infertility, this relationship should be pointed out with caution
considering that the increased cancer risk may be due to nulli-
parity and not to endometriosis itself. However, studies that
found a relationship were able to adjust for the effects of parity,
showing these relationships to be independent of each other [15].
Brinton et al. reported that women affected by endometriosis
presented a twofold risk of developing ovarian cancer than the
general population in a large cohort of 20,686 women hospital-
ized for endometriosis from 1969 to 1983 based on the National
Swedish Cancer Registry (SIR 1.9, 95% CI 1.3–2.8) [16]. The risk of
ovarian cancer was particularly increased among women with
a long-standing history of ovarian endometriosis (>10 years) (SIR
4.2 95% CI 2.0–7.7). The prolongation of this study, which enrolled
64,492 women from 1969 to 2000 still conﬁrmed this result (SIR
1.4; 95% CI 1.2–1.7) [17].
A recent report by Brinton et al. [1] evaluated the risk related
to endometriosis according to the different types of subfertility in
a large cohort of 12,193 women recruited in the US from 1965 to
1988. Overall infertile patients presented a signiﬁcantly higher
risk of ovarian cancer (SIR¼ 2.0; 95% CI 1.4–2.6) with the risk for
patients with primary infertility (SIR¼ 2.7; 95% CI 1.8–4.0) higher
than for patients with secondary infertility (SIR¼ 1.4; 95% CI 0.9–
2.3). Amongst infertile women, patients affected by endometriosis
had the highest risk with an SIR of 2.5 (95% CI 1.3–4.2) compared
to the general population and an SIR of 4.2 (95% CI 2.0–7.7) for the
group with primary infertility. Comparing the causes of infertility,
the SIR in women with endometriosis was 1.3 (95% CI 0.6–2.6).
When restricting the analysis to endometriosis and primary
infertility the SIR reached the value of 2.7 (1.1–6.7). At variance,
a recent Swedish cohort study by Melin et al., conducted on
63,630 women and 3822 cases of cancer, investigated the risk of
cancer in endometriosis stratifying for parity and reported
different data [15]. An increased risk of ovarian cancer with an SIR
of 1.36 was reported, but no signiﬁcant differences between
parous and nulliparous women with endometriosis, and a non-
signiﬁcant decrease in the risk of ovarian cancer with increasingPlease cite this article in press as: Cetin I et al., Infertility as a Cancer Risk FD
P
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F
parity. This study shows that the lack of parity is not the cause of
the increased ovarian cancer in this population: other risk factors
are likely to be involved in this association.
The association between ovarian cancer and endometriosis has
also been conﬁrmed by case–control studies. Ness et al. produced
ﬁndings in line with Brinton et al., reporting an OR of 1.73 (95% CI
1.1–2.7) in women with endometriosis compared to controls. The
underlining mechanisms seem to be attributable to immunological
and hormonal factors. In particular, studies of endometriosis in
patients with ovarian cancer reported a clear speciﬁc association to
malignant histotype, endometrioid and clear cell carcinomas [18–
20].
Although the current ﬁndings are strong enough to support
a link between endometriosis and ovarian cancer their association
cannot be used to infer causality. They may indeed represent two
distinct or two consequent entities as shown in Fig. 1.
2. Breast cancer and infertility
Several cohort studies of infertile women have reported an
incidence of breast cancer similar to that of the general population,
evenwithout adjustment for parity, with SIR ranging from 0.9 to 1.4
[1–3,6,12]. The slightly higher incidence in infertile women may be
related to the expected nulliparity and to late age at ﬁrst birth.
However, recently Jensen et al. reported a signiﬁcantly increased
SIR for breast cancer (SIR 1.08 95% CI: 1.01–1.16) in a large Danish
cohort, after adjustment for parity status [9].
Among the different causes of infertility, ovulation disorders,
characterized by an unbalanced estrogen environment, would have
expected to have a clear agreement vs higher risk, but the data are
not really conclusive [1–3,6].
Garland in a large prospective cohort of US women reported
that a multivariate RR value of 0.41 associated with a self-repor-
ted history of ovulatory infertility. A history of infertility,
excluding ovulatory infertility, also showed no increase in breast
cancer risk with RR¼ 1.06 (95% CI 0.76–1.48) [21]. These data are
in line with another prospective study that reported similar risk
of breast cancer (RR¼ 1.2; 95% CI¼ 0.7–2.0) in women affected by
polycystic ovary syndrome and in controls [22]. Moreover, the
recent prospective study by Terry et al. of infertility due to
ovulatory disorders and incidence of breast cancer found
a signiﬁcantly lower breast cancer risk in women reporting
infertility than in women who did not report infertility [23].
Case–control studies reported similar data with no increase in
breast cancer risk in all infertility types as well as in ovulatory
disorders infertility [24]. Data about association of breast cancer
and endometriosis are instead inconclusive. The initial report of
an increased risk in the Swedish cohort by Brinton et al. [16] was
not conﬁrmed by further studies [2]. The same is true for case–
control studies [25,26], reporting a signiﬁcantly increased OR in
premenopausal women, as if the two pathologies could share
a common inﬂammatory pathway [27].
3. Endometrial cancer and infertility
Cancer of endometrium has been associated with infertility by
a number of studies [2,4,9,28–35]. Comparing to the general pop-
ulation, two large cohort studies reported an increased risk of
endometrial cancer in infertile patients. Venn found an SIR of 2.47
for untreated IVF clinic patients, and Modan of 4.8 in patients
treated for infertility [2,4]. The recent large Danish cohort study
found a 29% borderline-signiﬁcant crude increased risk, but the risk
was not signiﬁcantly increased when results were adjusted for
parity [9].
Among ovulatory disorders, the association between polycystic
ovarian syndrome (PCOS) and endometrial cancer has beenactor – A Review, Placenta (2008), doi:10.1016/j.placenta.2008.08.007
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Fig. 1. Hypothesis of endometriosis and ovarian cancer association.
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reported by several studies. PCOS is the most common ovulatory
disorder and it is diagnosed in the presence of two or more of
chronic anovulation, clinical or biochemical signs of hyper-
androgenism, and polycystic ovaries (2003) Rotterdam criteria
[28].
In PCOS, the prolonged anovulation and consequent release of
estrogen unopposed by progesterone may enhance the develop-
ment and growth of endometrial cancer, particularly in young
women [29]. Hypersecretion of luteinizing hormone (LH), chronic
hyperinsulinemia and increased serum insulin-like growth factor 1
(IGF-1) levels may represent additional risk factors for endometrial
cancer [29], as shown in Fig. 2. An association between PCOS and
endometrial cancer was suggested since 1949 by Speert [30] and in
1957 by Jackson and Docherty [31]. However, there is only little
evidence to support a real association between endometrial cancerU
N
C
O
R
Fig. 2. Possible mechanisms implicated in the predisposition of polycystic ovarian
syndrome and predisposition to endometrial cancer.
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505Dand PCOS, and this evidence seems to be inconclusive [32]. More-
over, in a longitudinal study of 750 women with PCOS, mortality
from EC was not increased [33] and the prognosis for endometrial
cancer seemed better, since these cancers showed higher degrees of
differentiation [34]. These data are not in agreement with Pillay’s
report, where the immunohistological evidence of the proto-
oncogene Cyclin D1 seems to be more prevalent in endometrial
cancer of women with PCOS [35].
At present, it is not possible to reach a deﬁnitive conclusion,
since most studies have investigated the association between
endometrial cancer and anovulatory infertility, rather than PCOS,
while others have shown an association between PCOS and endo-
metrial hyperplasia, assuming the data could be extended to
endometrial cancer. Lastly, different deﬁnitions have been utilized
for PCO/PCO Syndrome. A recent study by Pillay et al. [35] inves-
tigated the prevalence of polycystic ovary (PCO), as a marker of
PCOS, in ovarian sections of women with endometrial cancer
compared to patients with benign conditions. The authors
concluded that PCO was similarly prevalent in the two groups;
however, in women aged <50 years, PCO was more prevalent in
women with endometrial cancer (62% vs 27%). More than 50 years
after an association between PCOS and endometrial cancer was ﬁrst
suggested, the nature of this association remains unclear [30,31].
4. Other cancers
The incidence of other extra-gynecological cancers has been
investigated by several studies inwomen affected by infertility, and
in particular by endometriosis. The incidence of invasive and in situ
cervical cancers in infertile women has been found to be signiﬁ-
cantly lower than expected from general population incidence rates
in two cohort studies [36,37]. These data may be explained by the
increased number of referrals to gynecologist from infertile
women, and the consequent more frequent cervical screening tests
which allow greater detection and treatment of low-grade lesions
before their progression to invasive cancer [16,36,37].
The incidence of melanoma has also been associated with
infertility. Rossing et al. reported melanoma to be signiﬁcantlyactor – A Review, Placenta (2008), doi:10.1016/j.placenta.2008.08.007
EO
F
Fig. 3. Action of clomiphene and possible action on breast and endometrial cancers.
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increased in infertile women [38] but this association was not
conﬁrmed by other studies [37]. The most recent study by Brinton
et al. [39] documented an increased twofold risk of melanoma in
infertile women with endometriosis compared to patients with
other causes of infertility.
An interesting recent ﬁnding, which needs further evidence to
be conﬁrmed, is also the possible association between endometri-
osis and Non-Hodgkin lymphoma reported by some studies
[16,17,39].
5. Ovulation induction and cancer risk
In the past years, much attention has been focused on the
possible association between the use of fertility medications (FMs)
and the development of malignancies of the ovary, breast, endo-
metrium, and thyroid gland as well as of melanoma. A number of
investigations have attempted to address the long-term effects of
ovulation-inducing medications on cancer risk, but most have had
shortcomings. These include small number of study subjects, short
follow-up, imprecise information on drug exposures and indica-
tions for usage, and absence of information on other correlates of
drug exposure that could inﬂuence cancer risk. Since hormonal and
reproductive factors are known to be involved in the etiology of
cancers of the female reproductive system, a stimulating effect of
fertility medications on the risk of these cancers is theoretically
possible. The precise mechanisms involved in the pathogenesis of
hormone-related cancers remain unclear, and thus, it is difﬁcult to
predict how and to which extent FM may affect the risk of various
cancers.
5.1. Ovarian cancer and ovulation induction
Ovarian cancer is the ﬁfth most common malignancy in women
in developed countries and accounts for approximately 4% of all
malignancies in females. In general, the highest incidence rates of
ovarian cancer are seen in North America and Scandinavia whereas
the lowest rates are seen in Asia. The large majority of ovarian
malignancies originates from the ovarian epithelium (80–90%).
Non-epithelial tumors of the ovary, such as germ cell tumors and
sex-cord tumors, originate from the ovarian stroma and account for
only 4–6% of all ovarian neoplasms.
To explain the epidemiology of epithelial ovarian cancer, three
main hypotheses have been developed. First, ovarian cancer might
be caused by repeated ovulations disrupting the ovarian epithelium
and leading to malignant transformation of the epithelial cells
[40,41].
The second hypothesis proposes a model in which persistent
stimulation of the ovary by gonadotropins increases the risk of
malignant changes [42]. The third hypothesis proposes a carcino-
genic role for exposure of the ovarian epithelium to environmental
agents, such as talcum powder, that may enter the pelvic cavity
through the vaginal canal. Talcum powder can be contaminated
with asbestos minerals known to be associated with excess
mortality from various cancers [43]. Recently, two new hypotheses
have been postulated. One is the ‘‘endometriosis hypothesis’’ where
endometriosis may act to promote the development of ovarian
cancer if endometriotic implants cause irritation and subsequent
inﬂammatory reactions [44]. The other hypothesis is that ovarian
cancer may be increased by factors associated with excess andro-
genic stimulation of ovarian epithelial cells and may be decreased
by factors related to greater progesterone stimulation.
Three lines of evidence raise concern regarding potential effects
of ovulation-inducing medications on cancer risk. First the most
commonly used medications, clomiphene citrate and gonadotro-
pins, are effective for stimulating ovulation, a factor implicated in
the etiology of both breast and ovarian cancers (Fig. 3). Second,Please cite this article in press as: Cetin I et al., Infertility as a Cancer Risk FD
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Othese medications raise both E2 and P levels, hormones that are
recognized as affecting the development and growth of breast and
gynecology cancers as well as some other cancers. Several clinical
reports have suggested a potential relationship between the use of
ovulation-inducing medications and ovarian cancer risk.
Rossing et al. [6] examined the risk of ovarian tumors in a cohort
of 3837 women evaluated for infertility between 1974 and 1985 in
Seattle. The authors found 11 invasive or borderline malignant
ovarian tumors, with a relative risk of 2.5 (95% CI,1.3–4.5). Although
the risk of an invasive epithelial ovarian tumor was somewhat
increased (age-standardized incidence ratio, 1.5; 95% CI, 0.4–3.7),
the risk of a borderline tumor was substantially higher than that
expected on the basis of rates in the general population of women
(age-standardized incidence ratio, 3.3; 95% CI,1.1–7.8). In particular,
Rossing et al. [6] found that, although the risk was increased
independently from the cause of infertility, it was roughly twice as
likely to develop in women with ovulatory abnormalities than in
the infertile women with other types of abnormalities. Moreover,
the authors described that ovarian tumors developed in nine of the
women who had used clomiphene, resulting in a higher risk than
that among infertile womenwho had never used the drug, and that
the women who used the drug for 12 or more cycles were at
considerably increased risk (adjusted relative risk, 11.1; 95% CI, 1.5–
82.3). These data suggested that prolonged use of clomiphene may
increase the risk of a borderline or invasive ovarian tumor.
However, the same authors [12] did not found an increased risk
in a population-based, case–control study among women aged 35–
54 treated with ovulation-inducing medications, including 378
cases and 1637 controls. Both among parous and nulliparous
women, the authors observed no association of cancer risk with
a history of infertility, medical evaluation for infertility, speciﬁc
types of infertility, or use of ovulation-inducing medications.
These contradictory data were reported also in a retrospective
study performed by Brinton et al. [45] to assess the long-term
effects of ovulation-stimulating medications on the risk of ovarian
cancer. Studying 12,193 patients, Brinton et al. evidenced that
infertile subjects had a signiﬁcantly higher risk of developing
ovarian cancer than the general population (standardized incidence
ratio 1.98; 95% CI 1.4, 2.6) and that the ovarian cancer risks were
similar in patients unexposed and exposed to clomiphene or
gonadotropins. To assess drug usage effects after accounting for
other factors that might inﬂuence ovarian cancer risk, the same
authors performed subsequent analyses on internal comparisons to
derive adjusted rate ratios and found that dosage and number of
cycles of FM were not associated with increased risk. Moreover,
there were higher, although non-signiﬁcant, risks with follow-upactor – A Review, Placenta (2008), doi:10.1016/j.placenta.2008.08.007
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time, with rate ratios after 15 or more years of 1.48 (95% CI 0.7, 3.2)
for exposure to clomiphene (ﬁve exposed cancer patients) and 2.46
(95% CI 0.7, 8.3) for gonadotropins (three exposed cancer patients).
Tables 1 and 2 present the principal studies reporting the rela-
tionship between the use of FM and ovarian cancer risk. Among
these studies, the results of Rossing did depend on population data,
whereas the studies of Brinton as well as Klip had internal
comparison groups [6,45,46].
Besides the attention pointed to the relationship between FM
and ovarian cancer risk, other studies have concentrated on expo-
sure during IVF programs. Venn et al. [2] studied the incidence of
cancer in 29,700 women who had undergone IVF treatment and
divided them into 20,656 patients exposed to fertility medications
and 9044 not exposed. The authors reported that the ovarian
cancer incidence was not greater than expected in the FM group
(SIR 0.91; 95% CI 0.74–1.13).
Similar results suggesting a low/no association between FM and
ovarian cancers were also reported in 25,152 women undergoing
IVF programs in the Netherlands [46] and in several studies char-
acterized by small and selected populations [10,47–49].
In conclusion, although the uninterrupted ovulation induced by
medications used for superovulation justiﬁes the potential link
between the use of fertility medications and ovarian cancer risk,
the studies published reported reassuring results. In addition, the
possible inﬂuence of dietary and genetic factors, hormonal status,
parity and other risk factors, indicates the need for new studies
characterized by a long follow-up and considering all confounding
factors.
5.2. Endometrial cancer and ovulation induction
Endometrial cancer ranks fourth among diagnosed cancers,
behind breast, lung, and bronchus and colon and rectum cancers. In
most industrialized countries, cancer of the corpus uteri is about as
frequent as ovarian cancer accounting for 6% of all new cancers.
Throughout her lifetime, a woman has a 1 in 37 chance of devel-
oping endometrial cancer. Recognized risk factors for endometrial
cancer are nulliparity, late age at menopause, obesity, PCOS, and
presence of estrogen-secreting malignancies. Anovulation, infre-
quent ovulations, and various progesterone deﬁciencies mostly
characterize hormonal subfertility. Irregular menstrual cycles are
often anovulatory or have a prolonged follicular phase. Both
features result in prolonged exposure to estrogen or progesterone
and this might raise the risk of endometrial cancer.
Two types of endometrial cancer have been described. Type I is
associated with hyperestrogenic states and expresses estrogen and
progesterone receptors. Type II is not associated with hyper-
estrogenism and functional receptors are rarely expressed. Much
like hormone-dependent breast cancer, the theory behind
hormone-dependent endometrial cancer is that estrogen stimu-
lates the mitotic activity of the endometrium, whereas it induces
differentiation. Increased cell division increases the probability of
random mutations, leading to cancer.
In 1994, Miannay et al. [50] described three cases of adenoma-
tous hyperplasia of the endometrium, occurring among women
treated with FM, but acknowledged the difﬁculty of establishing an
association between these hormonal therapies and adenocarci-
noma or its antecedents signs. In the same line of thought, most
studies have not observed an association between fertility medi-
cations and endometrial cancer [2,4,51] but most of these studies
show the limit of a follow-up time of less than 10 years.
Venn et al. [2] reported the ﬁndings of a follow-up study of
cancer incidence in 29,700 women who had referred for in vitro
fertilization (IVF) treatment. Interestingly, in these studies the
authors enrolled 20,656 women undergoing IVF treatment with
ovarian stimulation and 9044 women undergoing IVF but withoutPlease cite this article in press as: Cetin I et al., Infertility as a Cancer Risk FD
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treatment cycles. Cancers of the uterus were nomore common than
expected in IVF treated women (ﬁve observed, 4.6 expected, SIR
1.09, 95% CI 0.45–2.61) but theywere signiﬁcantlymore common in
patients referred for IVF but not treated (seven observed, 2.8
expected: SIR 2.47, 95% CI 1.18–5.18). In these studies cancers of the
uterus were diagnosed in women aged 35–48 and included eight
endometrial adenocarcinomas, two stromal sarcomas and three
leiomyosarcomas. Interestingly, all sarcomas were found in
untreated IVF patients.
Recently, two large studies have been performed studying the
effects of fertility medications on endometrium. Among 2496
infertile Israeli women treatedwith clomiphene or clomiphene and
human menopausal gonadotropins (hMG) between 1964 and 1974,
Modan et al. [4] described 21 endometrial cancers vs 4.3 expected
(SIR¼ 4.85, 95% CI 3.0–7.4), and evidenced that confounding by
nulliparity, obesity, and contraceptive use or hysterectomy could
not fully explain the increased risk ratio for endometrial cancer. The
authors also reported that endometrial cancer was prominent
among patients with normal estrogen production but progesterone
deﬁciency (SIR¼ 9.4, 95% CI 5.0–16.0).
Similarly, Althuis et al. [51] performed a retrospective cohort
study of 8431 US women (145.876 woman-years) evaluated for
infertility during 1965–1988 and described 39 uterine cancers.
Analysis of patients by questionnaire or by cancer and death
registries suggested that clomiphene may increase uterine cancer
risk (rate ratio (RR): 1.79; 95% conﬁdence interval (CI): 0.9–3.4). In
particular, women with an anovulatory disorder also were at
elevated risk of uterine cancer, whereas other causes of infertility
such as endometriosis, tubal disease, and male factor, uterine, or
cervical disorders were not related to uterine cancer risk. Moreover,
uterine cancer risk increased with clomiphene dose (RR: 1.93; 95%
CI: 0.9–4.0 for >900 mg), menstrual cycles of use (RR: 2.16; 95% CI:
0.9–5.2 for 6 cycles), and time elapsed since initial use (RR: 2.50;
95% CI: 0.9–7.2 for women followed for 20 years). Interestingly,
the risk was more strongly associated with clomiphene among
nulligravid (RR: 3.49; 95% CI: 1.3–9.3) and obese (RR: 6.02; 95% CI:
1.2–30.0) women.
In conclusion, the studies published as of today suggest an
increased risk of endometrial cancer in infertile patients with
hormonal defects where FM could accelerate cancer development.
However, the short follow-up and the lack of information on
important confounders, such as the cause of infertility or parity
represent a great limitation of some of the studies analyzed.
5.3. Breast cancer and ovulation induction
Breast cancer is the most common malignancy in women in
developed countries and accounts for 30–35% of all malignancies in
females. A one in eight women has the probability of developing
breast cancer during her lifetime. Breast cancers can be divided into
two groups: those whose growth is hormone dependent and those
that are not responsive to hormones. In general, the hormone-
responsive tumors are estrogen receptor positive and these ER-
positive tumors represent 60–75% of all breast cancer incidents.
These data suggest that breast cancer is associated to a hormonal
etiology and consequently ovulation induction medications could
contribute to cancer development.
In the last years several cohort and case–control studies were
performed to test this hypothesis. All these studies have not evi-
denced a greater risk in relation to fertility medications
[2,4,14,37,52–56], but they are limited by the small number of
cancers evaluated.
Among these studies, Burkman et al. [57] performed a case–
control study enrolling 4575 patients with histologically conﬁrmed
primary invasive breast cancer and 4682 control subjects without
breast cancer identiﬁed in the same geographic locations. Theactor – A Review, Placenta (2008), doi:10.1016/j.placenta.2008.08.007
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authors suggested that a history of infertility drug use was not
associated with the risk of developing breast cancer but evidenced
that women using human menopausal gonadotropin (hMG) for 6
months or for at least 6 cycles had a relative risk of breast cancer
ranging between 2.7 and 3.8.
Contradictory results were also reported in two large epidemi-
ological studies performed in Australia [2] and Holland [46]. Both
studies found no association between FM and cancer risk. However,
Venn et al. [2] described a twofold increased risk of breast cancer
within 1 year of last treatment, suggesting a possible role of fertility
medications to promote, but not to induce, a preexisting cancer.
Moreover, Gauthier et al. [58] reported that infertility treatment
was associated with an increased risk, of borderline signiﬁcance, of
breast cancer among womenwith a family history of breast cancer.
Finally, some studies suggested a preventive effect of clomi-
phene on breast cancer development. Clomiphene is a selective
estrogen receptor modulator (SERM) with similar properties to
another SERM such as tamoxifen. Two studies reported a reduced
risk in patients undergoing fertility medication with clomiphene
[59,60] and evidenced that the risk decreased signiﬁcantly with
duration of therapy. Contrary, Lerner-Geva et al. [61] observed 131
breast cancers in 5788 women attending ﬁve infertility centers in
Israel between 1964 and 1984 and reported that the risk for breast
cancer was signiﬁcantly higher for women treated with clomi-
phene citrate (SIR¼ 1.4; 95% CI 1.0–1.8). These results reached
statistical signiﬁcance even when well-known risk factors for
breast cancer (such as family history and cycle index) were
controlled for, suggesting that clomiphene may have a direct
antiestrogenic effects on the breast and that this effect may be
overridden by the elevated estradiol levels induced by clomiphene
in women of reproductive age.
Finally, Jensen et al. [9] analyzed a cohort of 54,362 womenwith
infertility referred to all Danish fertility clinics between 1963 and
1998 and found 331 invasive breast cancers. Analyses within
cohorts showed no overall increased breast cancer risk after use of
gonadotropins, clomiphene, human chorionic gonadotropin, or
gonadotropin-releasing hormone, whereas use of progesterone
increased breast cancer risk (RR, 3.36; 95% CI, 1.3–8.6). For all
groups of fertility drugs, no relationships with number of cycles of
use or years since ﬁrst use of fertility drug were found. However,
gonadotropins seemed to have a stronger effect on breast cancer
risk among nulliparous women (RR, 1.69; 95% CI, 1.03–2.77).
In conclusion, given that breast cancer is widely recognized as
having a hormonal etiology, further assessment on the effects of
fertility medications should be undertaken.
5.4. Other cancers
Melanoma is a cutaneous cancer and steroid hormones could be
involved in its pathogenesis. The changes in the hormonal levels
induced by fertility medications raise the question of possible
effects of FM in melanoma development.
In the largest IVF follow-up study evaluating risk of melanoma
in patients treated with fertility medications Klip et al. [46] repor-
ted 34 cases of melanoma and risk was not found to be increased in
treated women. Other studies characterized by a small number of
melanomas observed (Rossing et al. [38]: 12 cases; Venn et al. [2]:
12 cases; Young et al. [62]: 14 cases) reported similar results.
The greater incidence of thyroid cancer in women than men
may imply that female hormones are involved in the etiology of
thyroid cancer. Consequently some studies were performed to
assess fertility medications’ inﬂuence in thyroid cancer. In a retro-
spective cohort of 8422 women, Althius et al. [63] reported that
clomiphene or gonadotropins’ use did not signiﬁcantly increase risk
of thyroid cancer. Similar results were reported also by Kolonel et
al. [64] and La Vecchia et al. [65]. Recently, Hannibal et al. [66]Please cite this article in press as: Cetin I et al., Infertility as a Cancer Risk FD
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performed a follow-up study in 54,362 women with infertility and
identiﬁed 29 thyroid cancers. The authors evidenced that use of
clomiphene was associated with an increased risk of thyroid cancer
(RR¼ 2.28; 95% CI: 1.08–4.82), suggesting that longer follow-up
studies are needed to obtain conclusive results.
6. Limitations of studies assessing infertility and cancer risk
Whether infertile women are at increased risk of cancer due to
their infertility or factors such as ovulation medication induction,
has been the subject of several studies. Studies examining whether
infertility itself or ovulation induction are associated with an
increased risk have met considerable challenges. It is important to
consider these limitations in interpreting different studies reports:
differences of some studies may reﬂect the possible variability in
population selection. Overall, the limitations of these ﬁndings
include difﬁculties in achieving an adequate sample size, accurate
diagnosis of infertility, or data about treatment with infertility
medications with the respective dosages and duration exposure.
The interpretation of ﬁndings have to consider potential con-
founding risk factors that need to be identiﬁed and controlled such
as age at menarche, history of contraceptive use or hormone
replacement therapy, parity, age at ﬁrst birth, family history of
breast and ovarian cancer. Moreover, there is no study to our
knowledge, that has addressed potential differences between
gravidity or parity as confounding factors for cancer development
in infertile women.
Available studies can be generally subdivided in cohort or case–
control design. They both present advantages and disadvantages to
address this question.
Most cohort studies have selected their population from patients
from infertility clinics and as such reﬂecting cancer risk in a speciﬁc
population of women seeking medical treatment for infertility.
Cohort studies present the advantage that accurate information
about exposure to ovulation induction medications is available
from clinical records. A possible bias which should be taken into
account in interpreting these results is that the collected data are
speciﬁcally referred to the medical stimulation in that clinic,
ignoring possible treatments in other medical settings and, there-
fore, further data in terms of total number of cycle, type and
duration of medical treatment could be omitted. Therefore, these
studies cannot be generalized to all populations. Moreover, in some
cohort studies data about other potential biases that could arise
later, such as parity, contraceptive use, family history of breast or
ovarian cancer, could be omitted. Parity is the most relevant
confounder to adjust and stratify for, as the frequency of nulliparity
is higher among infertile women than among fertile women.
Otherwise, the cancer risk among infertile women will be over-
estimated as a consequence of the increased risk in nulliparous
women. Furthermore, most cohort studies present the inevitable
limitation of including a small number of cancer cases due to young
age for cancer development with short periods of follow-up.
Several cohort studies use the standardized incidence ratios (SIRs)
to compare cancer risk in infertile women with that of the general
population. This is a statistical parameter difﬁcult to interpret
because of the inability to control for other factors that might
distinguish cancer risks for infertile women.
Case–control studies populations are selected from hospitals in
some instances and from population-based registries in others.
They are limited by their ability in deﬁning and analyzing sepa-
rately patients with different causes of infertility. Moreover, they
rely on self-reported fertility drug use, which can be easily subject
to error when recalled after many years. Some studies have
determined the cause of infertility from medical records, but the
accuracy of data may vary according to infertility investigations,
clinical interpretation and deﬁnition of disease severity by theactor – A Review, Placenta (2008), doi:10.1016/j.placenta.2008.08.007
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different centers. However, differently from cohort studies most
case–control studies offer results corrected for parity.
In general, studies on cancer risk associated with infertility or
medications’ use are limited by low statistical power, in particular
when proposing a sub-analysis of infertility or type and time of
infertility treatment. Multicenter studies or pooled data by
different reports usually use common deﬁnition of population
characteristics andmodalities of recording data and reach adequate
sample size to give a precise estimation of the problem [10,11].
Meta-analysis do not offer a similar value, since they pool together
ﬁndings of individual heterogeneous studies, risking to add too
much bias in the ﬁnal considerations.
7. Conclusions
Epidemiological studies have suggested a possible association
between infertility, fertility drug use, and increased cancer risk.
Although ﬁndings are generally reassuring, nowadays we have no
ﬁrm answers in counseling infertile couples. Current evidence is
mostly based on case–control and cohort studies, which offer an
estimate of the problem. Larger population studies, better adjust-
ment for confounding factors, such as parity, infertility, contra-
ceptive use, early age at menarche, and late age at menopause,
which coexist in infertile patients, and long-term follow-up may
offer more precise data in the future. In particular, studies are
needed to better understand the patho-physiological mechanisms
underlying the apparent association between ovarian cancer and
infertility, as well as the association with endometriosis.
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